Hyperbaric Oxygen: Effective Against Cancer Radiation Harm?
Limited evidence and a significant time burden stand in the way of hyperbaric oxygen therapy becoming a more routine treatment for chronic radiation side effects in breast cancer.
Limited evidence and a significant time burden stand in the way of hyperbaric oxygen therapy becoming a more routine treatment for chronic radiation side effects in breast cancer.
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
An abstract is unavailable.
The OncoAlert Newsletter is now out for June 23-29, 2023
Venture beyond current limits with our latest perspectives in ovarian cancer care. Learn about new treatments, improving patient outcomes.
A breast cancer breakthroughs fundraising event, where you’ll learn about the progress our dedicated physician-scientists have made for today’s patients and the discoveries they’re pursuing…
Walking is a simple exercise that has many health benefits. Karen Basen-Engquist, Ph.D., shares tips on walking as exercise and how to increase the amount…
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
An abstract is unavailable.
18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.